Micromet to Present at the 2010 Future Leaders in the Biotechnology Industry Conference
BETHESDA, Md., March 24 /PRNewswire-FirstCall/ — Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the 2010 Future Leaders in the Biotechnology Industry Conference, to be held on April 8, 2010 in New York City. Christian Itin, Ph.D., the Company’s President and CEO, will present a 25 minute corporate overview on April 8 at 3:30 PM ET.
The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com. A replay of the webcast will also be available on the Company’s website.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTEÂ® technology, as well as conventional monoclonal antibodies. Two of Micromet’s BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.
SOURCE Micromet, Inc.